Board of Directors

board of directors
Eamonn Hobbs

Eamonn Hobbs

Chairman & Chief Executive Officer

Mr. Hobbs is an entrepreneurial senior executive with over 35 years of demonstrated success in profitable medical device and combination drug/device product business creation and growth, general management, sales and marketing, and product development.

He currently serves as a Visiting Scholar and Entrepreneur in Residence for the Translational Accelerator at Brigham and Women’s Hospital, Harvard Medical School. From July 2014 to January 2016, Mr. Hobbs served as the President and Chief Executive Officer of Antares Pharma, Inc., a specialty pharmaceutical and drug/device combination company focused on self-injection pharmaceutical products and technologies. From 2009 to 2013, he served as President and Chief Executive Officer of Delcath Systems, Inc., a specialty pharmaceutical and medical device public company specializing in cancer treatment.

Prior to Delcath, Mr. Hobbs served as President and Chief Executive Officer of AngioDynamics, Inc., a company he co-founded in 1988 as a division of E-Z-EM, Inc. which grew into a leading medical technology company and took public in 2004. Prior to starting AngioDynamics, Mr. Hobbs was Director of Marketing and Product Development at NAMIC; founder, President and Chief Executive Officer of Hobbs Medical, Inc.; and a Product Development Engineer at Cook Incorporated.

He also has served on numerous public and private company boards throughout his career. Mr. Hobbs received a B.S. degree in Plastics Engineering with a Biomaterials emphasis at the University of Massachusetts (Lowell).

Douglas Watson

Douglas Watson

Lead Independent Director

Mr. Watson is the former President and Chief Executive Officer of Novartis Corporation, the US subsidiary of Novartis AG. Mr. Watson’s career spanned 34 years with Geigy/Ciba-Geigy/Novartis, during which time he held a variety of positions in the UK, Switzerland and the US.

Mr. Watson joined Geigy (UK) Ltd in 1966, working first in Operations Research and then in Corporate Planning.  From 1986, he was President of Ciba US Pharmaceuticals Division until 1996, when he was appointed President & CEO of Ciba-Geigy Corporation. During this ten year period, Mr. Watson was an active member of the Pharmaceutical Research & Manufacturers Association (PhRMA) board in Washington, DC.

Mr. Watson became President & CEO of Novartis Corporation in 1997, when Ciba-Geigy & Sandoz merged. He elected to take early retirement from Novartis in May, 1999.

Mr. Watson currently serves as board member of BZL Inc., and a member of the advisory board of Cancer Expert Now Inc. Mr. Watson recently retired as Chairman of the board of OraSure Technologies Inc.

Prior board memberships include Novartis, Dendreon, Engelhard, Summit Bank, Wright Medical Group, BioMimetic Therapeutics, Delcath Systems, Javelin Pharmaceuticals, Genta, and Bionor Immuno AS.

Joseph Maroon, M.D.

Joseph Maroon, M.D.

Director

Dr. Maroon is a clinical professor and vice chairman of the Department of Neurological Surgery and Heindl Scholar in Neuroscience at the University of Pittsburgh Medical Center. He is regarded as a premiere specialist in the surgical treatment of injuries and diseases of the brain and spine, specializing in minimally invasive procedures. 

Consistently listed in America’s Best Doctors for the past 20 years, he has an international referral base, including numerous professional athletes and celebrities. Dr. Maroon has been the team neurosurgeon for the Pittsburgh Steelers since 1981 and is Medical Director of the World Wrestling Entertainment (WWE). 

Dr. Maroon has conducted extensive research into neurotrauma, brain tumors and diseases of the spine, which has led to many innovative techniques for diagnosing and treating these disorders. His research efforts garnered him numerous awards from various national and international neurological societies. He is the author of six books, and co-author of 40 book chapters and over 270 published scientific papers. He has given more than 150 presentations at national and international conferences and is often invited as visiting professor and key-note speaker. 

In addition to being a renowned neurosurgeon, he is a sports medicine expert, health and nutrition expert, Ironman triathlete and prolific author.

Charles Link, M.D.

Charles Link, M.D.

Director

Dr. Link is the Co-founder, Chairman and Chief Executive Officer of NewLink Genetics, a clinical stage company focused on the development of new immuno-oncology treatments. Dr. Link co-founded NewLink Genetics in 1999 with the idea of leveraging the body’s immune system to fight cancer. 

Dr. Link practiced oncology for 18 years, most recently caring for patients part-time at Medical Oncology and Hematology Associates of Iowa from 1995 to 2013. He also served as director of the Human Gene Therapy Research Institute, which is part of the John Stoddard Cancer Center at Iowa Methodist Medical Center.

Dr. Link was appointed by United States Senator John Glenn of Ohio to the United States Air Force Academy where he studied chemistry. Prior to graduating, he was accepted to a special program at Stanford University School of Medicine in Stanford, California, where he received his bachelor’s degree in chemistry and his medical degree. He interned at the University of California, San Francisco, and completed his residency and fellowship training in medical oncology at the National Cancer Institute in Bethesda, Maryland, where he also served as an attending physician.

Jeffery Cleland, Ph.D.

Jeffery Cleland, Ph.D.

Director

Dr. Cleland is the Executive Chair and Co-Founder of Orpheris, a clinical stage neuroscience company.  He has 25 years of industry experience in research and development, including more than a decade at Genentech, Inc. His experience in startups includes major roles in obtaining more than $450 million in capital at stages from Series A through D and exit via IPO including over $300 million in capital raised as CEO. As the founding CEO of Versartis (VSAR), he led one of top biotech IPOs of all time.

He has held executive management positions at BaroFold, Novacea and Targesome, and has managed directly all aspects of pharmaceutical development and late-stage research. While at Genentech, Dr. Cleland served in product development and manufacturing roles. He held important leadership roles in the successful approval of two drugs, Herceptin® and Nutropin Depot®, as well as in early work on Lucentis®, Avastin®, and Omnitarg®. 

He holds a BS in Chemical Engineering from the University of California, Davis and a PhD in Chemical Engineering from the Massachusetts Institute of Technology. Dr. Cleland has authored more than 100 articles and four books and holds several issued patents.

Norman Schwartz

Norman Schwartz

Director

Mr. Schwartz is the Chairman, President and CEO of Bio-Rad Laboratories, which provides innovative products and solutions for the life science research and clinical diagnostic markets. He assumed the Chief Executive Officer position in January 2003 after successfully running the Life Science and Diagnostics Groups of Bio-Rad. 

Since assuming the CEO role, the company listed on the NYSE and gained investment grade status for its debt securities.  The public value of Bio-Rad has increased eight-fold to $8 Billion, since 2003.

Mr. Schwartz also has extensive international experience, including Managing Director of the Microscience division in the U.K. and President of Nippon Bio-Rad in Japan.  He began his career with Bio-Rad in 1974, holding various operations, accounting and finance positions.  Mr. Schwartz received a Business Administration degree from California State University, San Francisco.